Cuban Abdala Vaccine: Effectiveness in Preventing Severe Disease and Death from COVID-19 in Havana, Cuba; a Cohort Study
Pedro Inocencio Más-Bermejo(Instituto de Medicina Tropical “Pedro Kourí”), Marta Ayala‐Ávila(Centro de Ingeniería Genética y Biotecnología), Merardo Pujol(Centro de Ingeniería Genética y Biotecnología), Kenia Almenares-Rodríguez, Isabel Morgado-Vega, Miladys Limonta‐Fernández(Centro de Ingeniería Genética y Biotecnología), Lizet Sánchez(Center of Molecular Immunology (Cuba)), Gerardo Guillén(Hunan City University), Verena L. Muzio‐González(Centro de Ingeniería Genética y Biotecnología), Francisco Hernández‐Bernal(Centro de Ingeniería Genética y Biotecnología), Felix Orlando Dickinson-Meneses(Instituto de Medicina Tropical “Pedro Kourí”), Yadira Olivera-Nodarse, Raúl Guinovart-Dı́az(University of Havana), María Vidal-Ledo, Enrique Galbán-García(Instituto de Gastroenterología), Santiago Dueñas‐Carrera(Centro de Ingeniería Genética y Biotecnología)
Cited by 23
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134